Document:

trtc_ex101.htm

EXHIBIT 10.1

 

SETTLEMENT AGREEMENT AND RELEASE

This Settlement Agreement and Release (this “Agreement”) is made as of the 16th day of April, 2014, by and between Terra Tech Corp., a Nevada corporation (the “Company”), and Amy Almsteier, a director and officer of the Company (the “Affiliate”).

 

WHEREAS, the Affiliate is subject to the reporting requirements of Section 16 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”);

 

WHEREAS, on March 13, 2014, the Affiliate sold 350,000 shares of common stock at a price of $1.2509 of the Company (the “March 13, 2014 Transaction”);

 

WHEREAS, on April 15, 2014, the Affiliate purchased 100,000 shares of common stock of the Company, at a purchase price of $0.58 per share (the “April 15, 2014 Transaction”); and

 

WHEREAS, the March 13, 2014 Transaction and the April 15, 2014 Transaction give rise to claims under Section 16(b) of the Exchange Act (the “Claim”), in the amount of $67,090 (the “Claim Amount”).

 

NOW, THEREFORE, in consideration of the mutual covenants contained herein, and intending to be legally bound, the parties hereby agree as follows:

 

1. Settlement and Release. The Affiliate agrees to pay and the Company agrees to accept $67,100 in full settlement and satisfaction of the Claim. The Company hereby agrees that upon receipt of the Claim Amount it will not take any further action against the Affiliate in connection with the Claim or matters relating thereto and releases Affiliate from the Claim. 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date set forth above.

 

 

	TERRA TECH CORP.	 	 	 
	 	 	 	 	 	 
	By:	

/s/ Derek Peterson

	 	
By: 

	/s/ Amy Almsteier	 
	Name:	Derek Peterson	 	Name:	
Amy Almsteier

	 
	Title:	President and CEOExhibit
10.15

 

JOINT
DEVELOPMENT AND SUPPLY AGREEMENT

 

This
Agreement is effective on the 15th day of November 2006 (the “Effective Date”) by and between

 

BASF
Aktiengesellschaft, 67056 Ludwigshafen, Germany acting also on behalf of its Affiliates (hereinafter referred to as “BASF”).

 

and

 

Cardax
Pharmaceuticals, Inc., Aiea, Hawaii 96701, USA (hereinafter referred to as “Cardax”).

 

BASF
and Cardax are referred to herein individually as a “Party” and collectively as the “Parties”.

 

Whereas
BASF develops, manufactures, markets and sells high-value performance chemicals, including fine chemicals for the pharmaceutical
industry;

 

Whereas
Cardax is developing proprietary pharmaceutical compounds;

 

Whereas
Cardax and BASF are interested in developing a process for the manufacture of the Product (hereinafter defined) with the intention
that BASF will manufacture the Product and Cardax will market or license human pharmaceuticals which utilize the Product as a
manufacturing intermediate;

 

Whereas
BASF received an inquiry from Cardax to prepare a proposal for process development and manufacturing of 3S, 3’S-Astaxanthin.
Cardax intends to use Product as an intermediate in the manufacture of or as an active ingredient in pharmaceutical or nutraceutical
products. After signature of the Confidentiality Agreement between Cardax and BASF dated 24.05.05/01.06.05, Cardax provided laboratory
information relating to an experimental protocol for the synthesis of homochiral Product and an analytical method for the determination
of the Astaxanthin stereoisomers and intermediates;

 

Now
therefore, in consideration of the above, it is hereby agreed as follows:

 

	1.	DEFINITIONS
	 	 
	1.1	“Affiliate”
    shall mean any corporation, company, partnership, joint venture and/or firm which controls, is controlled by, or is under
    common control with a specified person or entity. For purposes of this definition, “control” shall mean (a) in
    the case of corporate entities, direct or indirect ownership of more than fifty percent (50%) of the stock or shares having
    the right to vote for the election of directors, and (b) in the case of non corporate entities, direct or indirect ownership
    of more than fifty percent (50%) of the equity interest with the power to direct the management and policies of such non-corporate
    entities.

 

CERTAIN
PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES
EXCHANGE ACT OF 1934. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION.

 

    	 

    	 

    

 

	1.2	“Carotenoid
    Manufacturing Competitor” shall mean a manufacturer of synthetic carotenoids.
	 	 
	1.3	“Chemical
    Manufacturing Competitor” shall mean a chemical manufacturing business.
	 	 
	1.4	“Foreground
    Intellectual Property Rights” mean patents, trade, secrets and other confidential information, database rights, know-how
    and all other intellectual property and neighboring rights and rights of a similar or corresponding character in any part
    of the world and all applications for the protection of these rights, which cover Results.
	 	 
	1.5	“Net
    Nutraceutical Sales” shall mean total invoiced sales, as licensed in Section 4.4, made by BASF or its Affiliates to
    third parties in any calendar year after deduction of [***].
	 	 
	1.6	“Product”
    shall mean chemically synthesized 3S, 3’S-Astaxanthin with a specification of [***].
	 	 
	1.7	“Results”
    shall mean any development or modification in or to the Technology, whether patentable or not, conceived or developed under
    this Agreement.
	 	 
	1.8	“Technology”
    shall mean any discovery, invention, know-how, trade secret, sample of material, report, formulation, drawing and/or other
    works, technical information or data, together with any and all patent rights, relating to the manufacture of Product.

 

	2.	CARRYING
    OUT OF THE PROJECT

 

	2.1	The
    work, timing, resources, target profiles, milestones and payments for the performance of the work under this Agreement are
    documented in Appendix 1 of this Agreement. BASF shall use the same diligence and professional standards of performance consistent
    with those employed for BASF’s own affairs in performing the work.
	 	 
	2.2	The
    Parties agree and understand that the performance of the project within the agreed deadlines depends upon the accurate and
    timely allocation of necessary resources by both Parties.
	 	 
	2.3	Cardax
    will advise BASF in due time if the pilot material to be supplied by BASF will be for human clinical use and if the final
    synthetic step for the manufacture of Product will have to meet cGMP requirements. In the event Cardax requests more than
    the final synthetic step to be performed in accordance with cGMP, the Parties will negotiate in good faith a reasonable increase
    of the price for Product, corresponding to the increase in cost of production in order to meet cGMP requirements and a reasonable
    margin for BASF.

 

CERTAIN
PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES
EXCHANGE ACT OF 1934. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION.

 

    	2

    	 

    

 

	3.	CONFIDENTIAL
    INFORMATION
	 	 
	3.1	All
    information, plans for research and development, samples, technologies, or other matters disclosed or to be disclosed by either
    Party to the other in connection with this Agreement (including intermediate and final Results and Foreground Intellectual
    Property Rights) will be received and held in confidence by the recipient Party and shall be subject to the terms and conditions
    set forth for the exchange of Confidential Information defined in and covered by the Confidentiality Agreement entered into
    by and between the Parties on 24.05.05/01.06.05, modified in that the confidentiality obligations shall stay in effect for
    [***] following the expiration or termination of this Agreement, the laws of the Switzerland shall apply as specified in Section
    7.1 hereof, and disputes shall be settled as specified in Section 7.2 hereof. For the avoidance of doubt, the Parties agree
    that pursuant to Section 6.9 below, the royalty obligations of Section 4.4 hereof shall survive any future expiration of such
    confidentiality obligations.
	 	 
	3.2	All
    Confidential Information exchanged under this Agreement shall be used by the receiving Party solely internally within its
    organization for the performance of the project, as defined in Appendix 1, unless otherwise agreed by the disclosing Party,
    or explicitly stated otherwise in this Agreement.
	 	 
	3.3	Cardax
    may provide the Confidential Information to possible investors to the Cardax, but only provided that such investors have signed
    a confidentiality agreement containing essentially similar provisions of confidentiality as contemplated herein.
	 	 
	4.	INTELLECTUAL
    PROPERTY RIGHTS
	 	 
	4.1	The
    Parties agree that:
	 	 
	(a)	BASF
    shall have the entire and exclusive worldwide rights, title and interest in and to all Results relating to the manufacture
    of the Product (“BASF’s Interests”). BASF, at its sole discretion and expense, will have the right to prepare,
    file, prosecute, maintain and enforce patents and patent applications directed to BASF’s Interests.
	 	 
	(b)	Cardax
    shall have the entire and exclusive worldwide rights, title and interest in and to all Results relating to the formulation
    and the pre-clinical and clinical development of the Product as an intermediate in the manufacture of or as an ingredient
    in human pharmaceutical compounds (“Cardax’s Pharmaceutical Interests”) or nutraceutical compounds (“Cardax’s
    Nutraceutical Interests”) (collectively “Cardax’s Interests”). Cardax, at its sole discretion and
    expense, will have the right to prepare, file, prosecute, maintain and enforce patents and patent applications directed to
    Cardax’s Interests.

 

CERTAIN
PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES
EXCHANGE ACT OF 1934. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION.

 

    	3

    	 

    

 

	4.2	The
    Parties agree that any invention shall be and become the sole property of the relevant Party, as set out here above, which
    Party shall have the right to determine whether any application for a patent shall be made and shall have the exclusive benefit
    throughout the world of all Foreground Intellectual Property Rights, together with the right to maintain, assign or abandon
    such Foreground Intellectual Property Rights without reference to any other person. The Parties agree to execute and do all
    things necessary to vest the title and interest in such Foreground Intellectual Property Rights in the relevant Party as set
    out above, at the expense of said relevant Party, which shall pay the costs of the prosecution of all applications for Foreground
    Intellectual Property Rights to which it becomes entitled under this Agreement.
	 	 
	 	The
    Party intending to file a patent application shall inform the other Party of such intended filing and shall provide the other
    Party with an opportunity to comment on the text of the patent application, whenever this is possible without endangering
    protection. Further, not later than thirty days after the filing date, the Party filing the patent application shall furnish
    the other Party with a copy of the patent application, subject to the provisions of Article 3 here above.
	 	 
	4.3	Each
    Party shall keep the Results and any Foreground Intellectual Property Rights belonging to the other Party confidential and
    shall not, except as provided in this Agreement, use them without the prior written consent of the other Party or disclose
    it to any third party and shall treat it in accordance with the provisions of Article 3 here above.
	 	 
	4.4	Cardax
    hereby grants a non-exclusive worldwide, nontransferable license to BASF to use Cardax’s Nutraceutical Interests (but
    not Pharmaceutical Interests) for the purpose of development and commercialization (directly or through a third party) of
    human nutraceutical compounds containing or utilizing Product and to make available to BASF the reasonable assistance of Cardax
    in designing and conducting clinical studies in the United States therefor all subject to the negotiation and agreement by
    the Parties of reasonable commercial terms for such license and assistance. Such license shall be subject to the following
    tiered royalty structure:

 

 (a)

 

	 	(i)	[***]%
    on Net Nutraceutical Sales < $[***] 
	 	 	 
	 	(ii)	[***]%
    on Net Nutraceutical Sales of $[***] or more but < $[***] 
	 	 	 
	 	(iii)	[***]%
    on Net Nutraceutical Sales of $[***] or more but < $[***] 
	 	 	 
	 	(iv)	[***]%
    on Net Nutraceutical Sales of $[***] or more but < $[***] 
	 	 	 
	 	(v)	[***]%
    on Net Nutraceutical Sales of $[***] or above 

 

CERTAIN
PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES
EXCHANGE ACT OF 1934. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION.

 

    	4

    	 

    

 

BASF
shall have the option to have the license converted to an exclusive license, subject to the following provisions (b)- (d). BASF
shall exercise the option by written document at any time, subject to 4.4 (e) below.

 

	 	(b)	Tiered
    royalty structure

 

	 	(i)	[***]%
    on Net Nutraceutical Sales < $[***] 
	 	 	 
	 	(ii)	[***]%
    on Net Nutraceutical Sales of $[***] or more but < $[***] 
	 	 	 
	 	(iii)	[***]%
    on Net Nutraceutical Sales of $[***] or more but < $[***] 
	 	 	 
	 	(iv)	[***]%
    on Net Nutraceutical Sales of $[***] or more but < $[***] 
	 	 	 
	 	(v)	[***]%
    on Net Nutraceutical Sales of $[***] or above

 

	 	(c)	Commercialization
    obligations

 

	 	(i)	[***]
	 	 	 
	 	(ii)	[***]

 

	 	(d)	If
    BASF fails the commercialization obligations, Cardax may terminate by written notice to BASF the exclusivity of the license.
    In such event, the license shall become non-exclusive and the tiered royalty schedule set out in 4.4 (a) shall apply as of
    the date of the notice.
	 	 	 
	 	(e)	If
    at any time prior to the execution of the option with respect to an exclusive license, Cardax gives BASF written notice that
    Cardax desires to [***], BASF’s right to exercise the option shall [***].
	 	 	 
	 	(f)	Any
    license (either non-exclusive or exclusive) granted pursuant to this agreement or contemplated by this agreement to BASF by
    Cardax for Cardax’s Nutraceutical Interests shall terminate [***].

 

	4.5	[***]
	 	 
	4.6	[***]

 

CERTAIN
PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES
EXCHANGE ACT OF 1934. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION.

 

    	5

    	 

    

 

	5.	COMMERCIAL
    EXPLOITATION
	 	 
	5.1	BASF
    agrees to supply Cardax with up to [***] kg of Product for use by Cardax in preclinical and human clinical trials, to be supplied
    at the prices and on the terms and conditions set forth in Appendix 1.
	 	 
	5.2	[***],
    BASF shall exclusively manufacture the Product for Cardax or its licensees for use as an intermediate in the manufacture of
    or as an ingredient in human pharmaceutical or [***] compounds, and Cardax or its licensee shall exclusively purchase from
    BASF all of its clinical trial and commercial requirements of Product for such use. The Parties agree that the supply and
    purchase of Products shall further be governed by the terms outlined in Appendix 2 hereto and such further terms as may be
    set out in a definitive Supply Agreement to be negotiated in good faith by the Parties and that the Parties shall, prior to
    the commencement by Cardax of the first [***] of a compound which utilizes [***] as an [***] or as an [***] (the “Supply
    Date”), conclude a written Supply Agreement in accordance with such terms. In case Cardax decides to transfer Cardax’s
    Interests to a third party, Cardax shall procure that such third party assumes the obligations of Cardax under the Supply
    Agreement, including the obligation to exclusively purchase the Product from BASF, and, subject to such assumption by the
    third party, BASF shall perform its obligations under the Supply Agreement for the benefit of the third party, including the
    obligation to exclusively manufacture the Product for the third party and its licensees.
	 	 
	5.3	In
    consideration of the rights granted pursuant to this Agreement, except as set forth in Section 4.4 above, BASF shall not,
    during the term of this Agreement, [***], directly or indirectly through one or more third parties, the [***].
	 	 
	6.	TERM
    AND TERMINATION
	 	 
	6.1	This
    Agreement is valid as of the date first set forth above (the “Effective Date”) and will continue until the end
    of the third year thereafter. After this initial term of three years, it shall automatically be prolonged by periods of [***]
    each unless terminated by either Party giving [***] written notice prior to the end of the initial term or any prolongation
    term.
	 	 
	6.2	In
    the event that both Parties agree that the Project is not technically or commercially viable, this Agreement may be terminated
    forthwith, upon decision by the Parties to this effect.
	 	 
	6.3	This
    Agreement may be terminated immediately by either Party should the other Party be in breach of any material obligation imposed
    upon it by the terms of this Agreement and shall not have remedied such breach (if capable of remedy) within [***] days of
    written notice to the other Party specifying the breach and requiring such remedy.

 

CERTAIN
PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES
EXCHANGE ACT OF 1934. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION.

 

    	6

    	 

    

 

	6.4	This
    Agreement will terminate immediately should any Party to it become insolvent, shall have a receiver appointed or the whole
    or any material part of its assets or shall have any order made or resolution passed for it to be wound up (otherwise than
    in furtherance of a scheme for amalgamation or reconstruction details of which shall have been notified to the other Party).
	 	 
	6.5	Each
    Party may terminate this Agreement if any third party not being an affiliated company of the other Party shall acquire an
    interest in more than fifty percent of the issued equity share capital or voting capital of the other Party. This provision
    shall not apply if such an interest in Cardax is acquired by an entity that is not a Chemical Manufacturing Competitor.
	 	 
	6.6	BASF
    shall be entitled to terminate this agreement in writing without notice period if BASF in its own discretion decides to exit
    the business of manufacture of Astaxanthin. However, upon request of Cardax, BASF shall make available a stock of Product
    in order to cover Cardax’s requirements for a transition period, [***]. Except as provided in Section 6.8 and in the
    Supply Agreement, there shall be no compensation rights of Cardax or any third party arising from such termination.
	 	 
	6.7	Either
    Party may terminate this Agreement in writing without notice period if any of the milestones listed in Appendix 1 hereto is
    not reached within the timeframe indicated in Appendix 1 plus [***] and the Parties could not agree to a prolongation of such
    timeframes.
	 	 
	6.8	In
    the event of termination of this Agreement by either Party in accordance with Sections 6.1 and 6.6, the terminating Party
    shall, upon request of the other Party, grant the other Party a reasonable royalty-bearing, irrevocable, worldwide, non-exclusive
    license, with the right to sublicense, to use BASF’s Interests (if BASF is the terminating Party) or Cardax’s
    Nutraceutical Interests (but not Cardax’s Pharmaceutical Interests) (if Cardax is the terminating Party), including
    such assistance and advice as may be reasonably required to enable the other Party to exercise the rights licensed to it;
    excluding, however, the license or transfer of any rights that are not part of the Foreground Intellectual Property Rights.
	 	 
	6.9	The
    provisions of Sections 3, 4, 6.6, 6.8, 7 and 8 shall survive the expiry or termination of the present Agreement.
	 	 
	7.	LAW
    AND ARBITRATION
	 	 
	7.1	This
    Agreement shall be governed in all respects by, and be construed and governed in accordance with the laws of Switzerland excluding
    its conflicts of law principles and excluding any application of the United Nations Convention on the International Sale of
    Goods.

 

CERTAIN
PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES
EXCHANGE ACT OF 1934. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION.

 

    	7

    	 

    

 

	7.2	If
    a controversy, claim or dispute arises out of or relates to any provision of this Agreement or the breach thereof, and including
    the validity of any provisions thereof, the Parties will make all efforts to find a mutually acceptable solution. In the absence
    of such an agreement within [***] days after the date at which one Party has notified the other Party that a dispute exists,
    the dispute shall be finally settled, ousting jurisdiction by ordinary courts, by a three-member arbitral tribunal in accordance
    with the arbitration rules of the International Chamber of Commerce. The unsuccessful party shall bear the costs of the proceedings
    and the costs and expenses incurred by the successful party for the proper conduct of the matter. Where no party is completely
    successful, the costs of the proceedings and the costs and expenses incurred by the parties for the proper conduct of the
    matter shall be shared proportionately. The seat of the arbitration shall be New York City and New York City shall be the
    location where all proceedings will be conducted. The language for the proceedings shall be the English language.
	 	 
	8.	GENERAL
    PROVISIONS
	 	 
	8.1	Neither
    Party is entitled to assign, transfer, charge, encumber or otherwise deal with the whole or any part of this Agreement or
    its obligations hereunder provided, however, that either Party may assign this Agreement, without the consent of the other
    Party, (i) to any of its Affiliates, if the assigning Party guarantees the full performance of its Affiliates’ obligations
    hereunder, provided however, that the Affiliate shall be obliged to re-assign the Agreement and all rights and obligations
    thereunder to Cardax once the Affiliate ceases to be an Affiliate of Cardax, or (ii) in connection with the transfer or sale
    of all or substantially all of the assets or business to which this Agreement relates or in the event of its merger or consolidation
    with another company, provided however, that BASF shall in such event enjoy the rights of [***] and [***] set out in Section
    4.5 and 4.6 herein.
	 	 
	8.2	Other
    than as specified in this Agreement or otherwise agreed in writing, nothing in this Agreement shall imply, create, grant or
    transfer any license or authority in respect of any intellectual property including patents, designs, trademarks, copyrights
    or confidential information or know-how. Except as specified in this Agreement nothing in this Agreement shall be construed
    as providing a commitment of any kind to enter into or modify any further agreement, undertake or modify any further obligation,
    accept or modify any liability or purchase any goods or services. This Agreement shall not constitute the Parties partners
    or either Party the agent of the other for any purpose.
	 	 
	8.3	Other
    than as specified in this Agreement, the Parties shall at all times be free to engage in research, development and/or supply
    programmes and agreements with third parties relating to or encompassing their respective know-how, information, data and/or
    experience.
	 	 
	8.4	Any
    notices given under this Agreement shall be in writing and sent to the recipient Party’s address as indicated at the
    head of this Agreement.

 

CERTAIN
PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES
EXCHANGE ACT OF 1934. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION.

 

    	8

    	 

    

 

	8.5	This
    Agreement and any Appendix hereto, as well as the Confidentiality Agreement dated 24.05.05/01.06.05, as expressly modified
    pursuant to Section 3.1, contain the entire understanding of the Parties as to the subject matter, supersedes all prior and
    collateral communications, reports and understandings between the Parties relating to the subject matter and cannot be modified
    except by a written document bearing the signatures of both Parties hereto.
	 	 
	8.6	All
    communications between the Parties with respect to any of the provisions of this Agreement will be sent to the addresses set
    out below, or to other addresses as designated by one Party to the other by notice pursuant hereto, by internationally recognized
    courier or by prepaid certified, air mail (which shall be deemed received by the other Party on the seventh business day following
    deposit in the mails), or by facsimile transmission or other electronic means of communication

 

If
to BASF, at:

BASF
Aktiengesellschaft

[***]

67117
Limburgerhof

GERMANY

 

If
to Cardax at:

 

Cardax
Pharmaceuticals, Inc.

David Watumull

99-193 Aiea Heights Drive Suite 400

Alea, HI 96701

 

IN
WITNESS WHEREOF, the Parties have executed this Agreement as of the date first set forth above.

 

Made
in two originals in Honolulu, Hawaii USA on October 13, 2006.

 

	Cardax
    Pharmaceuticals, Inc.	 	BASF
    Aktiengesellschaft
	 	 	 	 	 	 	 
	By:	/s/ David G.
    Watumull	 	By:	/s/ Martin
    Jager	 	/s/
    Sacha Reichardt
	 	 	 	 	 	 	 
	Title:	President &
    CEO	 	Title:	Director	 	Legal
    Counsel

 

CERTAIN
PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES
EXCHANGE ACT OF 1934. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION.

 

    	9

    	 

    

  

APPENDIX
I

to the

Joint Development and Supply Agreement

between BASF AG and Cardax Pharmaceuticals, Inc.

 

The
following project proposal was developed based on the Cardax information and on BASF process knowledge for racemic Astaxanthin.

 

		A.	Milestones

 

It
is proposed to conduct the project in discrete steps (Milestones). Each milestone will define clear go-no go positions; the completion
of the milestones are essential for the successful completion of the project.

 

Milestone
1. 

 

[***]

 

Upon
acceptance of BASF’s proposal by Cardax BASF will provide an updated [***] for the project.

 

Completion
Date: [***] after the Effective Date of this Agreement

 

Milestone
2. 

 

[***]

 

Completion
Date: [***] weeks after Completion of Milestone 1

 

Cost:
[***] EUR, payment due within [***] days after date of invoice from BASF

 

Milestone
3. 

 

[***]

 

Completion
Date: [***] weeks, start parallel to Milestone 1; completion after [***]

 

Cost:
[***] EUR, payment due within [***] days after date of invoice from BASF

 

Milestone
4. 

 

[***]

 

Completion
Date: [***] weeks after Completion of Milestone 3

 

Cost:
[***] EUR. The first payment of [***] EUR will be due within [***] days after BASF has announced the start of its work. After
successful completion at BASF’s discretion, the second payment of [***] EUR will be due within [***] days after date of
invoice from BASF.

 

    	10

    	 

    

 

Milestone
5. 

 

[***]

 

Completion
Date: Within [***] weeks after successful completion of Milestone 4

 

Milestone
6. 

 

[***]

 

[***]kg

 

Completion
Date: [***] weeks after Completion of Milestone 5

 

Total
product cost: [***] EUR; payment due within [***] days after date of invoice from BASF

 

Or

 

[***]
kg

 

Completion
Date: [***] weeks after Completion of Milestone 5

 

Total
product cost: [***] EUR; payment due within [***] days after date of invoice from BASF

 

Or

 

[***]
kg

 

Completion
Date: total of [***] weeks after Completion of Milestone 5

 

Total
product cost: [***] EUR; payment due within [***] days after date of invoice from BASF

 

Additional
quantities ([***] kg, [***] weeks per [***] kg) beyond the [***] kg batch: [***] EUR/kg, to be specified as needed and dependent
of appropriate timing.

 

    	11

    	 

    

  

Milestone
7. 

 

[***]

 

Duration:
[***]

 

Cost:
[***]

 

		B.	Progress
                                         Reports

 

Upon
completion of each milestone BASF will provide Cardax with a written progress report detailing an updated time and cost estimate
for the remaining milestones based on the experience made and ask Cardax for clearance to begin the following milestone. In case
unforeseen problems occur during elaboration of a milestone, BASF will immediately inform Cardax specifying the effect of such
problems on further development and on cost and time estimates any work requiring additional time of more than [***] to complete
or additional cost of more than [***]% shall be subject to the prior written approval of Cardax.

 

		C.	Payment

 

Payment
by Cardax of the costs associated with each milestone will be due as defined above. If the project is terminated by Cardax, Cardax
will pay to BASF all costs reasonably incurred until the date of termination.

 

    	12

    	 

    

 

APPENDIX
2

To the Joint Development and Supply Agreement

between BASF Aktiengesellschaft and Cardax Pharmaceuticals, Inc.

Terms of Supply of Product

Subject to the negotiation and execution by the Parties of a mutually acceptable

definitive Supply Agreement

 

A
Supply Agreement between the Parties would include, but not be limited to, the following terms:

 

A.[***],
BASF shall exclusively supply the Product to Cardax and its licensees for use as an intermediate in the manufacture of or an ingredient
in human pharmaceutical or [***] compound, and Cardax and its licensees shall exclusively purchase their requirements of Product
exclusively from BASF or BASF’s affiliates for such use, including clinical supplies, and for commercial supplies, for a
period of [***] years from the earliest date of commercial introduction of the Product or any compound that contains the Product,
subject to earlier termination under the provisions of the Supply Agreement. The term of the Supply Agreement shall be subject
to extension upon mutual agreement of the Parties.

 

B.The
purchase price for the Product shall be calculated according to the formula attached hereto as Schedule l. Payment shall be made
within [***] days after the date of invoice without any deductions, except as may be specifically set forth in the Supply Agreement.

 

C.Every
[***] months, Cardax will submit to BASF its best estimates of its requirements of Products for the following [***] months period,
providing forecasted volumes split by [***]. Cardax undertakes to purchase and take a minimum amount of Products of [***]% of
the latest forecast for the [***] concerned (“Minimum Amount”). BASF shall make its reasonable best efforts to meet
Cardax’s requirements, provided that BASF shall not be required to supply Product in excess of the latest forecast by more
than [***]% ([***] percent) and BASF shall not be obliged to sell and deliver more than [***] of Products in any [***] months
period. Firm and binding purchase orders for the quantities of Products shall be placed by Cardax in writing at least [***] working
days prior to the desired delivery date.

 

    	13

    	 

    

 

D.Products
supplied to Cardax shall conform to the specifications to be agreed upon by the Parties and to requirements of applicable laws
and regulations. There is no other warranty or representation of BASF of any kind, especially with regard to the merchantability,
the quality or the fitness of the Products for any use and none shall be implied by law.

 

E.Cardax
has the duty to examine the Products upon delivery. Unless claims concerning quality or quantity of Product are raised by Cardax
without undue delay within [***] days following receipt of the respective delivery or, in case of hidden defects that cannot be
detected upon reasonable inspection, without undue delay following detection, but no later than [***] days after delivery, the
Products delivered shall be deemed to be accepted. If the Product does not meet the agreed to specifications, Cardax’s sole
remedy and BASF’s sole liability to Cardax is limited to replacement of the nonconforming Product or payment in an amount
not to exceed the purchase price of the specific Product for which damages are claimed, at BASF’s option. Except as provided
in the patent indemnity below and in any indemnity for third party claims (backed by applicable insurance for Cardax) which the
Parties may agree to during Supply Contract negotiations, the liability of either Party to the other Party shall not exceed in
the aggregate [***]. Neither Party will in any event be liable for any loss of profits, loss of use, or any indirect, incidental,
consequential or special damages of any kind whatsoever.

 

F.Any
and all claims in relation to the delivery of Products, except for claims in case of liability due to death or personal injury,
are subject to a statute of limitation of 2 (two) years.

 

G.BASF
shall indemnify Cardax for infringement of third party rights to the extent arising from manufacture of the Product, and Cardax
shall indemnify BASF for infringement of third party rights to the extent arising from its further formulation of the Product
as well as the manufacture, storage, sale, distribution and any other use of its finished products or intermediates containing
the Product.

 

    	14

    	 

    

 

H.The
Supply Agreement shall be governed by and construed in accordance with the substantive laws of the State of New York, USA, including
its provisions of the Uniform Commercial Code, but excluding its conflicts of law principles and excluding any application of
the United Nations Convention on the International Sale of Goods.

 

I.Any
dispute arising out of or in connection with the supply of Product that cannot be settled amicably between the Parties shall be
finally resolved as provided in Section 7.2 of the Agreement.

 

J.In
the event that BASF cannot supply for any reason, BASF shall [***]. As such [***] solely in order to [***] for Cardax, [***].
Upon resolution of the supply interruption, all [***] under this paragraph shall [***] and [***], to assure that Cardax [***].
The following shall be deemed to constitute a failure of supply for this purpose: [***]% of any ordered quantity is not delivered
within [***] business days following the committed delivery dates, or if so delivered, is not in material compliance with the
agreed specifications.

 

K.Upon
request of Cardax, BASF shall [***], as designated by Cardax, [***], provided that Cardax give BASF sufficient notice and agrees
to [***] (a) before Cardax [***], and (b) at the termination or expiration of the Contract.

 

L.The
Supply Agreement shall contain other reasonable and customary provisions including, without limitation, provisions relating to
termination, patents and intellectual property, recalls, adverse event reporting, packaging, manner of payment, taxes, determination
of compliance with specifications, delivery procedures, inventory, audits and inspections, supply interruption, force majeure,
Purchaser financial / credit status, indemnification, indemnification procedures, and regulatory requirements and qualifications.

 

M.BASF
shall be entitled to terminate any supply contract without notice period if BASF in its own discretion decides to exit the business
of manufacture of Astaxanthin. There shall be no compensation rights of Cardax or any third party arising from such termination.
However, upon request of Cardax, BASF shall make available a stock of Product in order to cover Cardax’s requirements for
a transition period not to exceed the greater of: [***].

 

    	15

    	 

    

 

Schedule
1

 

Purchase
price index chemicals (PPIC) BASF AG in [***] is [***].

 

Purchase
price in EUR/kg [***] (Incoterms 2000):

 

	●	Volume
                                         of [***] but less than [***]:

 

Purchase
price according to Appendix I, Milestone 6

 

	●	Volume
                                         of [***] or more:

 

[***]

 

    	16

    	 

    

 

AMENDMENT
NO. 1

TO

JOINT DEVELOPMENT AND SUPPLY AGREEMENT

 

This
Amendment No. 1 is entered into effective on the 15th day of April 2007 (the “Amendment Effective Date”) with respect
to the Joint Development and Supply Agreement entered into effective the 15th day of November, 2006 (the “JDSA”) by
and between

 

BASF
Aktiengesellschaft, 67056 Ludwigshafen, Germany acting also on behalf of its Affiliates (hereinafter referred to as “BASF”).

 

and

 

Cardax
Pharmaceuticals, Inc., Aiea, Hawaii 96701, USA (hereinafter referred to as “Cardax”).

 

BASF
and Cardax are referred to herein individually as a “Party” and collectively as the “Parties”.

 

Whereas,
BASF develops, manufactures, markets and sells high-value performance chemicals, including fine chemicals for the pharmaceutical
industry;

 

Whereas,
Cardax is developing proprietary pharmaceutical compounds;

 

Whereas,
the JDSA involves the joint development and supply of 3S, 3’S Astaxanthin (defined for purposes of this Amendment as the
“Original Product” and defined in the JDSA as the “Product”) which can be used as an intermediate in the
manufacture of an active ingredient in pharmaceutical products or as a nutraceutical product;

 

Whereas,
Cardax has developed and owns an active pharmaceutical ingredient 3S, 3’S Astaxanthin-[***] (the “New Product”)
which can be manufactured using the Original Product as an intermediate;

 

Whereas,
pursuant Section 4.1(b) of the JDSA, Cardax owns the exclusive rights to the formulation and pre-clinical and clinical development
of the Original Product as an intermediate in the manufacture of an active ingredient in pharmaceutical products, including the
New Product as such a pharmaceutical product;

 

Whereas,
the Parties desire that Cardax market or license the New Product as a pharmaceutical product (but not as a nutraceutical product)
and that BASF manufacture and supply the New Product to Cardax and its licensees for this purpose.

 

    	17

    	 

    

 

Now
therefore, in consideration of the above, it is hereby agreed as follows:

 

	1.	BASF
                                         agrees to supply the New Product exclusively to Cardax or its licensees under the same
                                         terms and conditions as contained in the JDSA and its Appendix 2 entered into between
                                         the Parties for the Original Product, except as outlined in Section 2 below.
	 	 
	2.	For
                                         avoidance of doubt, the Parties acknowledge and agree that the New Product is not a [***].
	 	 
	3.	The
                                         milestone plan and feasibility costs for the New Product shall be as set forth in Appendix
                                         1 to this Amendment No. 1. Pricing for [***] (Milestone 4), [***] (Milestone 5), [***],
                                         and [***] of the New Product shall be [***].
	 	 
	4.	Subject
                                         to the foregoing, the JDSA shall continue in full force and effect in accordance with
                                         the provisions thereof.

 

IN
WITNESS WHEREOF, the Parties have executed this Amendment No. 1 as of the Amendment Effective Date set forth above.

 

Made
in two originals in _Ludwigshafen_____________ on April 24, 2007.

 

	Cardax Pharmaceuticals, Inc.	 	BASF Aktiengesellschaft
	 	 	 	 	 
	By:	/s/
    Thomas H. Goodin	 	By:	/s/
    Martin Jager
	 	 	 	 	 
	Title:	VP Preclinical
    and Clinical Operations	 	Title:	DIRECTOR
	 	 	 	 	 
	 	 	 	By:	/s/
    Uwe Pressler
	 	 	 	 	Senior Counsel
    IP

 

    	18

    	 

    

 

APPENDIX
I

to the

Extension of the Joint Development and Supply Agreement

between BASF AG and Cardax Pharmaceuticals, Inc.

 

The
following project proposal was developed based on the Cardax information and on BASF process knowledge for 3S,3’S-Astaxanthin-[***].

 

		A.	Start
                                         Date

 

It
is agreed between Cardax Pharmaceuticals and BASF AG that the project shall start 15, April 2007.

 

		B.	Milestones

 

It
is proposed to conduct the project in discrete steps (Milestones). Each Milestone will define clear go-no go positions; the completion
of the Milestones are essential for the successful completion of the project.

 

Milestone
1. 

 

[***]

 

Completion
Date: [***]

 

Cost:
[***] €, payment due within [***] days after date of invoice from BASF

 

Deliverables:
Monthly progress reports

 

Go/No
go decision (to proceed to Milestone 2 and in parallel Milestone 3, or to extend Milestone 1, or stop)

 

Milestone
2. 

 

[***]

 

Completion
Date: [***]

 

Go/No
go decision (to proceed or stop)

 

[***]

 

    	19

    	 

    

  

Milestone
3. 

 

[***]

 

Cost:
[***] €, payment due within [***] days after date of invoice from BASF

 

Completion
Date: [***]

 

Milestone
4. 

 

[***]

 

Completion
Date: [***]

 

Cost
and payment schedule: [***]

 

Milestone
5. 

 

[***]

 

Completion
Date: [***]

 

Cost
and payment schedule: [***]

 

		C.	Progress
                                         Reports

 

Upon
completion of each Milestone BASF will provide Cardax with a written progress report detailing an updated time and cost estimate
for the remaining Milestones based on the experience made and ask Cardax for clearance to begin the following Milestone. In case
unforeseen problems occur during elaboration of a Milestone, BASF will immediately inform Cardax specifying the effect of such
problems on further development and on cost and time estimates any work requiring additional time of more than [***] to complete
or additional cost of more than [***] % shall be subject to the prior written approval of Cardax.

 

		D.	Payment

 

Payment
by Cardax of the costs associated with each Milestone will be due as defined above. If the project is terminated by Cardax, Cardax
will pay to BASF all costs reasonably incurred until the date of termination.

 

    	20

    	 

    

 

		

 

January 14, 2014

 

BASF SE

Carl-Bosch-Straße 38

67056 Ludwigshafen

Germany

 

We refer to the Joint Development
and Supply Agreement (as amended or supplemented, the “Agreement”) dated with effect on the 15th
day of November, 2006 by and between BASF SE (formerly named BASF Aktiengesellschaft), acting also on behalf of its Affiliates
(collectively, “BASF”) and Cardax Pharmaceuticals, Inc., a Delaware corporation (“Cardax Holdings”).
Cardax Pharma, Inc., a Delaware corporation (“Pharma”), is a subsidiary of Cardax Holdings. On May 31,
2013, Pharma assumed all of the obligations and was assigned all of the rights of Cardax Holdings.

 

By executing and delivering
to us a copy of this letter, you agree that:

 

(1) all
rights and obligations of Cardax Holdings under the terms of the Agreement have been assigned to, and assumed by, Pharma and,
accordingly, all references to “Cardax” in the Agreement shall be a reference to Pharma; and

 

(2) BASF
has previously exercised its option in Article 4.4 of the Agreement to convert the non-exclusive license to use
Cardax’s Neutraceutical Interests (as defined in the Agreement) into an exclusive worldwide license in accordance with
the terms of the Agreement.

 

We look forward to continuing
our long-standing relationship with you.

 

	 	Sincerely,
	 	 
	 	/s/ David
    G. Watumull
	 	David G. Watumull
	 	President and CEO

 

[continued on the following page]

 

    	 

    	 

    

 

 

BASF SE

Page 2

 

Accepted and agreed as of the date

of this letter first written above.

 

BASF SE

 

	/s/
    Ceranski	 	/s/
    Corinna Klopprogge
	Name:	Ceranski	 	Name: 	Dr. Corinna Klopprogge
	Title: 	SVP	 	Title:	Senior Counsel IP
	 	 	 	 	Global Intellectual Property

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00229-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00229-of-00352.parquet"}]]